Michael M. Vickers

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial

Cathy Eng, Tae Won Kim, Johanna C. Bendell et al. · The Lancet Oncology · 2019 · 562 citations · Full text

Medicine, Oncology, Pharmacology +11

Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial

Derek J. Jonker, Louise Nott, Takayuki Yoshino et al. · ˜The œLancet. Gastroenterology & hepatology · 2018 · 168 citations

Medicine, Oncology, Pharmacology +7

Stage-dependent differential expression of microRNAs in colorectal cancer: potential role as markers of metastatic disease

Michael M. Vickers, Jair Bar, Ivan Gorn‐Hondermann et al. · Clinical & Experimental Metastasis · 2011 · 112 citations

Medicine, Molecular Biology, Oncology +17

Clinical Outcome in Metastatic Renal Cell Carcinoma Patients After Failure of Initial Vascular Endothelial Growth Factor-Targeted Therapy

Michael M. Vickers, Toni K. Choueiri, Miranda J. Rogers et al. · Urology · 2010 · 78 citations

Medicine, Cancer Biology, Oncology +14

Prognostic Factors of Survival for Patients With Metastatic Renal Cell Carcinoma With Brain Metastases Treated With Targeted Therapy: Results From the International Metastatic Renal Cell Carcinoma Database Consortium

Michael M. Vickers, Hulayel Alharbi, Toni K. Choueiri et al. · Clinical Genitourinary Cancer · 2013 · 71 citations

Medicine, Nephrology, Oncology +15